2023 ESMO研究速递:改变未来前列腺癌临床实践的研究  

2023 ESMO express:research on changing clinical practice for prostate cancer

作　　者：戴波 王珊珊[1,2] 叶定伟 Dai Bo;Wang Shanshan;Ye Dingwei(Department of Urology,Fudan University Shanghai Cancer Center;Department of Oncology,Shanghai Medical College,Fudan University,Shanghai 200032,China)

机构地区：[1]复旦大学附属肿瘤医院泌尿外科 [2]复旦大学上海医学院肿瘤学系,上海200032

出　　处：《中华泌尿外科杂志》2023年第12期885-888,共4页Chinese Journal of Urology

摘　　要：2023欧洲肿瘤内科学会年会(ESMO)于近日召开。此次会议对全球肿瘤学领域最前沿的研究进行了深入探讨,并发布了多项前列腺癌领域的重磅结果本文对其中根治手术后放疗的最佳时机、生化复发的新型药物治疗、转移性激素敏感性前列腺癌的疗效预测、以及骨保护剂应用的新价值等重要研究进行解读和点评,以期为临床治疗决策提供帮助。The 2023 European Society for Medical Oncology(ESMO)was held recently.In this conference,numbers of cutting-edge studies were discussed and published including advances in diagnosis and treatment,especially in prostate cancer.Studies that may influence clinical treatment decisions were summarized in this article,including timing of radiotherapy after radical prostatectomy,Enzalutamide in biochemically recurrent prostate cancer,predictive factors of novel hormonal therapies in metastatic hormonesensitive prostate cancer,and the value of osteoprotective agent.The purpose of this article was to help clinicians make better clinical decisions.

关 键 词：前列腺癌 研究进展 雄激素受体抑制剂 

分 类 号：R737.25[医药卫生—肿瘤]